Novavax has been gearing up to launch a phase 3 trial of what may result in an important product: A combined flu and coronavirus vaccine. But the company now faces a roadblock, saying regulators ...

In early pandemic days, Novavax (NASDAQ: NVAX) shares soared as investors bet on the company's ability to bring a coronavirus vaccine to market. But as the biotech fell behind in the race and ...

Nov 5 (Reuters) - Novavax (NVAX.O), opens new tab said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency (UKHSA) related to its COVID-19 ...

Shares in Novavax fell by as much as one-fifth Wednesday morning after the company disclosed the Food and Drug Administration halted clinical testing of its combination vaccine for COVID-19 and ...

Graeme Sloan / Bloomberg via Getty Images The Food and Drug Administration put clinical holds on Novavax's COVID-19 and flu combination vaccine and its standalone flu shot because of safety concerns.

Novavax ( (NVAX)) has issued an announcement. Novavax, Inc. and the UK Health Security Agency have reached a settlement to terminate their SARS-COV-2 Vaccine Supply Agreement, resolving disputes ...

Novavax’s plans for growth outside of its COVID program have been thrown into chaos after the FDA put two of the biopharma's programs on hold in response to a case of nerve disease from a former ...

Oct 16 (Reuters) - The U.S. Food and Drug Administration has put on hold a trial of Novavax's (NVAX.O), opens new tab COVID-influenza and its standalone flu vaccines after a participant who took ...

Shares of Novavax (NASDAQ:NVAX) fell roughly 30% Wednesday morning after the U.S. FDA put a clinical hold on the new drug application of its COVID-19 and influenza combination vaccine and ...

FDA places a clinical hold on Novavax's COVID-19-influenza vaccine trials due to a serious adverse event in a Phase 2 participant. Novavax's COVID-19 IND and European approval for its updated ...